DPYD and cancer: In a study of about 200 Caucasian cancer patients treated with FL-based therapy, De Mattia et al., 21 demonstrated that the burden of rare and novel DPYD variants is significantly higher among patients with toxicity, compared to patients without toxicity by sequencing all exons, splice junctions, 3'/5' UTR and proximal promoter region of the DPYD gene.